ArticleClinical pharmacology in drug development2018

Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC.

Eng-Huat Tan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.